October 1, 2014 / 8:28 PM / 3 years ago

BRIEF-Esperion Therapeutics announces positive top line phase 2b results for ETC-1002

Oct 1 (Reuters) - Esperion Therapeutics :

* Esperion Therapeutics Announces Positive Top Line phase 2b results for ETC-1002

* Says ETC-1002-008 study meets primary endpoint; ETC-1002 appears to be safe and well tolerated

* Says ETC-1002 lowers LDL cholesterol significantly more than merck's zetia-study Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below